OncoMatch/Clinical Trials/NCT07250269
Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis
Is NCT07250269 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1 trial studies GC012F for relapsed/refractory al amyloidosis.
Treatment: GC012F — This is a Phase 1b open-label, multicenter, non-randomized study of GC012F, a CD19/BCMA dual CAR T cell therapy, in adult participants with relapsed/refractory AL amyloidosis.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Multiple Myeloma
Disease stage
Excluded: Stage MAYO STAGE IIIB AL AMYLOIDOSIS
Mayo Stage IIIb AL amyloidosis
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: anti-plasma cell-directed therapy
Relapsed disease or refractory disease defined as a need for additional therapy after at least 1 line of anti-plasma cell-directed therapy.
Cannot have received: CAR-T cell therapy
Prior CAR T cell therapy directed at any target
Cannot have received: BCMA-targeting therapy
Prior BCMA-targeting therapy
Lab requirements
Cardiac function
Oxygen saturation < 95% on room air; Systolic blood pressure <100mmHg; NT-proBNP > 8500ng/L and high sensitivity cardiac troponin T ≥ 50 ng/L or cardiac Troponin T ≥ 0.035 ng/mL or cardiac Troponin I ≥ 0.1 ng/mL; NT-proBNP ≥ 2000 ng/L (dose escalation); NT-proBNP < 2000 and > 8500 ng/L (dose extension); NYHA class III or IV
Oxygen saturation < 95% on room air; Systolic blood pressure <100mmHg; Mayo Stage IIIb AL amyloidosis as defined by NT-proBNP>8500ng/L, and high sensitivity cardiac troponin T ≥ 50 ng/L cardiac Troponin T ≥ 0.035 ng/mL or cardiac Troponin I ≥ 0.1 ng/mL; NT-proBNP levels as follows: NT-proBNP ≥ 2000 ng/L (for dose escalation portion), NT-proBNP < 2000 and > 8500 ng/L (for dose extension portion); NYHA class III or IV
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07250269 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior CAR-T cell therapy, BCMA-targeting therapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages